<DOC>
	<DOCNO>NCT00199602</DOCNO>
	<brief_summary>This Phase III open-labed , multicenter , prospective , randomise study , comparative 3-arms 140 patient ( i.e . 420 total patient ) . Study period ( date first inclusion/last inclusion ) : 3 year Treatment period : 3 month</brief_summary>
	<brief_title>Prophylaxis Thrombosis With Implantable Devices Central Venous Access Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>First line chemotherapy solid tumor : Metastatic disease Involved nod Unresectable tumor Indication Implantable device central venous access Potential survival &gt; 3 month ECOG performance status 0 2 ( WHO ) Age 18 75 year . Social security guarantee Normal laboratory assessment ( platelet &gt; 100000/mm3 , TP 60 % , spontaneous TCA M/T &lt; 1.5 , TGO TGP &lt; 2xN , serum creatinin &lt; 120Âµmol/l ) Informed consent sign Inability understand inform consent interfere compliance treatment protocol Anticoagulant treatment related criterion Acute infectious endocarditis History relate heparin allergy thrombopenia due heparin Uncontrolled high blood pressure ( systolic blood pressure &gt; 180 mm Hg and/or diastolic blood pressure &gt; 110 mm Hg ) Hemorrhagic syndrome ongoing Patient platelet inhibitor treatment Chronic , daily treatment anticoagulant therapy ( LMWH AVK ) , use preventive curative level Patient liver failure ( TP &lt; 60 % ) renal insufficiency ( creatinin clearance &lt; 20 ml/mn ) Women pregnancy lactate Pathologyrelated criterion deep venous thrombosis history pulmonary embolism ( &lt; 6 month ) Clinical suspicious brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>